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Abstract
Determining whether persons with multiple sclerosis (MS) receive appropriate, comprehensive healthcare requires tools
for measuring quality. The objective of this study was to develop quality indicators for the care of persons with MS. We
used a modified version of the RAND/UCLA Appropriateness Method in a two-stage process to identify relevant MS
care domains and to assess the validity of indicators within high-ranking care domains. Based on a literature review,
interviews with persons with MS, and discussions with MS providers, 25 MS symptom domains and 14 general health
domains of MS care were identified. A multidisciplinary panel of 15 stakeholders of MS care, including 4 persons with MS,
rated these 39 domains in a two-round modified Delphi process. The research team performed an expanded literature
review for 26 highly ranked domains to draft 86 MS care indicators. Through another two-round modified Delphi
process, a second panel of 18 stakeholders rated these indicators using a nine-point response scale. Indicators with a
median rating in the highest tertile were considered valid. Among the most highly rated MS care domains were appro-
priateness and timeliness of the diagnostic work-up, bladder dysfunction, cognition dysfunction, depression, disease-
modifying agent usage, fatigue, integration of care, and spasticity. Of the 86 preliminary indicators, 76 were rated highly
enough to meet predetermined thresholds for validity. Following a widely accepted methodology, we developed a
comprehensive set of quality indicators for MS care that can be used to assess quality of care and guide the design of
interventions to improve care among persons with MS.
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Introduction
Multiple sclerosis (MS) is a neurological disorder that
aﬀects 400,000 people in the United States.
1 Gaps in
care quality exist for many chronic diseases
2,3 and have
been reported for aspects of MS care.
4 However, gaps
in many other aspects of MS care have not been stud-
ied. Identifying gaps in care quality requires tools for
measuring the quality of comprehensive MS care.
Understanding why gaps in care quality exist is funda-
mental to designing healthcare delivery system
interventions.
5,6
The quality of medical care can be measured
through medical care processes or patient outcomes.
7
While traditional MS measures such as the Expanded
Disability Status Scale (EDSS) scores are appropriate
for assessing outcomes of participants enrolled in ran-
domized controlled trials (RCTs), they are less useful
outside of such settings because diﬀerences in outcomes
1Department of Neurology, David Geffen School of Medicine, University
of California, Los Angeles, CA, USA.
2Department of Neurology, VA Greater Los Angeles Health Care
System, Los Angeles, CA, USA.
3Department of Medicine, David Geffen School of Medicine, University of
California, Los Angeles, CA, USA.
4Multiple Sclerosis Center of Excellence-East, Research and Neurology
Services, VA Maryland Health Care System, Baltimore, MD, USA.
5Department of Neurology, University of Maryland School of Medicine,
Baltimore, MD, USA.
6Multiple Sclerosis Center of Excellence-West, VA Puget Sound Health
Care System, Seattle, WA, USA.
7Department of Rehabilitation Medicine, University of Washington
School of Medicine, Seattle, WA, USA.
8Departments of Epidemiology, University of Washington School of
Medicine, Seattle, WA, USA.
9Department of Medicine, VA Greater Los Angeles Health Care System,
Los Angeles, CA, USA.
Corresponding author:
Eric Cheng, MD, MS, VA Greater Los Angeles, 11301 Wilshire Boulevard,
Department of Neurology, ML 127, Los Angeles, CA 90073, USA
Email: eric.cheng@va.govmay be attributable to factors other than the quality of
medical care delivered.
As an alternative to patient outcomes, major stake-
holders in healthcare have developed and used quality
indicators to measure processes of care.
8,9A scientiﬁ-
cally rigorous methodological approach called the
RAND/UCLA Appropriateness Method (RAM) is a
widely utilized technique for developing indicators to
measure processes of care in many conditions, includ-
ing neurological conditions such as stroke,
10,11
Parkinson’s disease,
12 dementia,
13 and epilepsy.
14 The
goal of RAM is to identify processes of care to which
adherence is strongly associated with better health
outcomes.
We applied RAM to develop a comprehensive set of
quality indicators to measure the quality of healthcare
of persons with MS.
Materials and methods
Overview of the stages and techniques pursued in
the research study
We used a modiﬁed version of the RAM in a two-stage
process to (1) identify relevant MS care domains
and then (2) draft indicators and rate their validity
(Figure 1). Because MS is characterized by a wide spec-
trum of symptoms and available disease-modifying and
symptom-targeted treatments,
15–17 there is a vast
number of potential quality indicators that could be
drafted for MS care. By ﬁrst identifying the most
important domains for MS care, the research team
could then prioritize a resource-intensive literature
review to identify candidate indicators.
An overview of the RAM is presented here. RAM is a
systematic method of combining evidence with expert
judgment and contains characteristics of both the
Delphi method and nominal group techniques.
18–20
First, a research team performs a comprehensive
review of the literature. Based on the literature review,
the research team drafts a set of items to be rated, and
mails these items to panelists to be rated in private with-
out consulting one another. Panelists then mail their rat-
ingsback to theresearch team.A face-to-face meetingof
the panelists is then convened to review the de-identiﬁed
ratings, discuss reasons for disagreement in ratings, and
anonymously re-rate the items. Finally, the research
team applies pre-determined statistical thresholds of
the ratings to identify items of high importance.
Assembly of an expert panel of nationally recognized
MS stakeholders
We identiﬁed 17 general health and MS-speciﬁc orga-
nizations that comprehensively represent stakeholders
of MS care (see the list in the acknowledgements) and
obtained from each organization a list of nominees who
could serve on a panel to rate MS care domains. We
selected nominees to attain a diverse range of clinical
disciplines and geographical locations. We invited our
ﬁrst-choice nominees to participate, and they all
accepted, and we refer to this group as Panel 1.
Panelists were not told which organization nominated
them and were instructed to rate items based on their
own perspective and not from the perspective of any
organizations to which they are aﬃliated. The multi-
disciplinary panel comprised major stakeholders of
MS care including four persons with MS, directors of
MS patient advocacy organizations, neurologists, reha-
bilitation physicians, nurses, therapists, and healthcare
administrators.
First stage
Generating a comprehensive set of MS care domains
We used three sources of data to inform development
of a comprehensive set of MS care domains. First, we
interviewed a convenience sample of 10 persons with
MS across diﬀerent mobility stages receiving care at
the VA Greater Los Angeles (VA GLA) or University
of California, Los Angeles (UCLA) to understand their
perspectives on living with MS. A semi-structured inter-
view tool that assessed demographics, MS symptoms,
physical functioning, emotional well-being, social func-
tioning, current MS symptoms and care, and outlook
for the future was used during these sessions. All inter-
views were audiotaped, and summaries of each inter-
view were shared with the research team.
Next, the research team performed a systematic
review of PubMed using Medical Subject Headings
terminology, and then performed reference mining of
relevant studies. We also reviewed the websites of the
National Guideline Clearinghouse,
21 Cochrane
Database of Systematic Reviews,
22 United States
Preventive Services Task Force (USPSTF),
23
American Academy of Neurology,
24 and the National
Multiple Sclerosis Society
25 for guidelines, indicators,
reviews, and large trials providing or summarizing sci-
entiﬁc evidence relevant to MS care. The International
Classiﬁcation of Functioning, Disability and Health
established by the World Health Organization was
used to organize an initial set of 70 MS care domains.
26
The research team deleted domains that were not well
supported by the literature review and combined others
to reduce redundancy. Individual phone calls with pan-
elists were arranged to obtain feedback on revising the
list of MS care domains. A ﬁnal set of 39 MS care
domains were mailed to panelists, including 25 MS
symptoms in at least one of four mobility stages of
Cheng et al. 971disease: ambulatory without assistance, ambulatory
with assistance, wheelchair user, and bed-bound as
well as a list of 14 general health domains that are
applicable across mobility stages.
Rating MS care domains
Each panelist was mailed a booklet for rating the MS
care domains and a monograph summarizing the liter-
ature review. First, panelists were instructed to sort an
Research steps
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Figure 1. Flow diagram of items drafted by research team and then rated by the two panels.
972 Multiple Sclerosis 16(8)equal number of MS symptoms within a mobility stage
of disease into three tiers of order of importance: high-
est level of importance, second highest level of impor-
tance, and third highest level of importance. Second,
panelists were instructed to sort general health domains
into three tiers of order of importance. Third, panelists
designated three general health domains as indispens-
able to MS care.
The second round of ratings occurred during a sub-
sequent face-to-face meeting of the panel. Panelists
were given their own unique summary rating sheets
that contained the de-identiﬁed initial distribution of
ratings by the entire panel, as well as a reminder of
that particular panelist’s own ratings. Thus, panelists
could determine how their own ratings compared with
the distribution of the entire panel’s ratings, but they
could not determine the ratings of any other particular
panelist. The members of the research team moderated
the discussion to limit the role of any dominant mem-
bers and encouraged participation from the entire
panel. Finally, once discussion of a set of domains
was complete, the panelists conﬁdentially re-rated the
domains using identical criteria to those used in the ﬁrst
round.
Second stage
Generating a comprehensive set of MS
quality indicators
The highly rated MS care domains guided a subsequent
literature review for drafting quality indicators. Similar
of sources used to identify MS care domains were again
used to identify potential indicators. Indicators were
worded in the form of an ‘IF...THEN...’o ra n
‘ALL persons with MS SHOULD...’ statement. An
external team of an MS specialist, rehabilitation physi-
cian, and an MS nurse not related to the research proj-
ect reviewed each indicator and suggested further
changes to enhance clarity. Ultimately, 88 indicators
were drafted across 26 domains of MS care. For
Panel 2, several domains were consolidated, reducing
the number to 24 domains.
Rating MS quality indicators
All persons who rated the domains in the ﬁrst year were
invited to participate in the second panel, which we refer
to as Panel2. Because theliterature review forindicators
in Panel 2 contained more clinically technical informa-
tion than that for domains in Panel 1, additional clini-
cians were invited for Panel 2 to ensure there was
suﬃcient expertise to evaluate each indicator. Panel 2
comprised 18 persons, including 4 persons with MS.
A rating booklet and a monograph summarizing the
literature supporting each indicator were mailed to the
members of Panel 2. Panelists were asked to rate each
indicator using a nine-point visual scale of validity, with
higher numbers indicating greater validity (see Table 1
for deﬁnition of validity and visual scale provided to
Panel 2). This deﬁnition of validity was adapted from
prior RAM studies.
19,27 Similar to Panel 1, the research
team created personalized feedback sheets for panelists
that reminded the panelists of their ﬁrst round rating
and provided the anonymous distribution of ratings of
the entire panel for each indicator.
The second round of ratings occurred during a sub-
sequent face-to-face meeting. Panelists were given the
opportunity to suggest changes in phrasing for each
indicator. Next, the research team invited discussion
Table 1. Definition of the criteria of validity used by Panel 2 to rate MS quality indicators
1. Evidence and opinion supports a link between an indicator and positive MS patient outcomes such as
  mortality
  symptoms
  functional status
  mental health
  satisfaction with care, and
  compliance with evidence-based treatments AND
2. An indicator that applies to a larger proportion of the eligible population will have more impact on the health of the population
and thus should have a higher level of validity than an indicator that applies to only a few people, AND
3. An indicator that has a greater impact on the health of an individual person (such as management of phenylketonuria) should
have a higher level of validity than an indicator that has a smaller impact on the health of an individual person (such as
management of eczema).
Lowest level
of validity
Highest level
of validity
123456789
« Decline to answer
Cheng et al. 973of the indicator, particularly when there was lack of
consensus in the ﬁrst round ratings for an indicator.
Panelists then discussed the basis for their ﬁrst round
ratings, then conﬁdentially re-rated the indicators.
Analysis
For the domains of MS symptoms, the one-third of
domains with the highest number of panelists rating
that domain in the top tier were considered the most
important for that stage of disease. For example, of the
22 domains applicable to the MS population who
ambulate without assistance, we designated the 8
domains with the highest number of panelists voting
them into their top tier as the most highly rated
(domains tied for the eighth highest ratings in the top
tier were included in the set of most highly rated
domains). For the general domains of MS, we included
all domains that a panelist identiﬁed as indispensable to
MS care.
Because the criteria for rating quality indicators used
an ordinal scale and the frequencies across the scale
values were not normally distributed, indicators were
ranked by their median instead of mean ratings.
Indicator projects that use a 1–9 rating scale of validity
typically accept indicators in the highest tertile of the
scale (median ratings of 7, 8, or 9) as valid.
3,19,27
Wilcoxon rank-sum tests were used to compare the
ratings between the 4 panelists with MS versus the
14 panelists without MS.
While all indicators that meet thresholds for validity
are suitable for measuring quality, measurement pro-
grams of healthcare organizations do not have the
resources to implement all of them. To provide a
basis by which a subset of indicators could be selected,
we categorized the ﬁnal set of valid indicators accord-
ing to four criteria that may be pertinent to a measure-
ment program. The ﬁrst criterion is the strength of the
panel’s rating, deﬁned as a high median rating on valid-
ity ( 8) and narrow dispersion of ratings ( 80% of
panelists rated indicator in highest tertile). The second
criterion is the frequency with which an indicator was
expected to be applicable (deﬁned as applicable to at
least 20% of cases within a particular year based on
prevalence data identiﬁed in the literature review).
The third criterion is the level of evidence supporting
an indicator (deﬁned as results from an RCT or
endorsement by one of the following organizations:
the US Food and Drug Administration, the Centers
for Disease Control, or the USPSTF). The fourth cri-
terion is the means of measurement, identifying those
indicators that could be measured using administrative
data.
We obtained approval from the Institutional Review
Boards at VA GLA and UCLA to conduct this study.
Written informed consent was obtained from all sub-
jects participating in the patient interviews.
Results
Among the MS-speciﬁc domains, bladder dysfunction,
cognitive dysfunction, depression, fatigue, and spastic-
ity were highly rated by Panel 1 in at least three of the
four mobility stages (Online Table 1). A total of 16
domains fell in the top tier within at least one stage
of disease. The 10 general domains of MS care rated
highly by Panel 1 are listed in Online Table 2. The
general domains that received the most votes by
Panel 1 for being indispensable to MS care were ‘At
time of diagnosis: Medical evaluation-appropriateness
and timeliness’, ‘Disease-modifying agents’, and
‘Establishment, integration, and coordination of care’.
During the face-to-face discussion of indicators by
Panel 2, several indicators were reworded for clarity,
and a few indicators were consolidated to reduce redun-
dancy, reducing the number of rated indicators by 2 to
86 indicators. There were 76 indicators with a ﬁnal
median rating of atleast 7, thepre-set threshold ofvalid-
ity (Table 2 and Online Table 3). The remaining 10 indi-
cators had a median rating below 7 and were excluded
from further development (Online Table 4). The
domains with the highest number of valid indicators
include bladder dysfunction, disease-modifying agents,
management of exacerbations and activities of daily
living diﬃculties, and general preventive care (Table 3).
The median rating of validity by the 4 panelists with
MS was within one point of themedian rating of validity
by the 14 panelists without MS for 76 (86%) indicators
(data not shown). The ratings for two indicators were
signiﬁcantly diﬀerent between these two groups by
Wilcoxon rank-sum tests (p<0.05): ‘‘Assessment of
problems with work or education’’ was rated lower by
panelists with MS versus panelists without MS (median
rating of 7.5 versus 3) and ‘‘All persons with MS should
be assessed for spasticity annually’’ was rated higher by
panelists with MS versus panelists without MS (median
rating of 9 versus 7).
The 76 valid measures vary in their suitability for
diﬀerent measurement programs (Online Table 3).
There are 57 indicators that met a higher threshold of
validity. Based on the literature review we concluded
that 66 indicators will likely be commonly triggered
among persons with MS but 10 indicators will likely
be infrequently triggered. There are 19 indicators that
are directly supported by results from RCTs or are
endorsed by a key healthcare organization. There
were 14 indicators in Online Table 3 that met the
above three criteria of a higher validity threshold, com-
monly triggered, and are supported by either RCTs or
by a key healthcare organization. Finally, based on our
974 Multiple Sclerosis 16(8)Table 2. Abbreviated name of 76 valid indicators
Domain Abbreviated text of MS indicators that met thresholds for validity
Domains of MS symptoms
Anxiety Management of anxiety
Bladder Dysfunction/ Urinary
Tract Infection (UTI)
Assessment of urinary symptoms
Assessment for UTI upon hospital admission
Management of post-void residual urine
Avoid treatment of asymptomatic bacteriuria
Test for antibiotic susceptibility with recurrent UTI
Work-up of chronic subjective bladder symptoms
Bowel Dysfunction Assessment for bowel function
Management of constipation
Work-up of fecal incontinence
Cognitive Dysfunction Assessment for cognitive deficits
Management of cognitive deficits
Depression Assessment for depression
Treatment of depression
Fatigue Assessment of fatigue
Work-up for fatigue
Review of medications causing fatigue
Management of primary fatigue
Mobility/Falls Assessment for mobility impairments
Work-up of mobility impairments or falls
Pressure Ulcers Assessment for risk of pressure ulcers
Assessment for pressure ulcers in long-term facility
Use of specialty mattresses
Prevention of pressure ulcer
Relapses Documentation of occurrence of relapses
Differentiate relapse from pseudo-relapse
Sexual Dysfunction Assessment of erectile dysfunction
Management of erectile dysfunction
Assessment of female sexual dysfunction
Work-up of sexual dysfunction
Referral to specialist with expertise in sexual problems
Spasticity Assessment of spasticity
Work-up of spasticity
Management of persistent spasticity
Speech Management of dysarthria
Swallowing Assessment of dysphagia
Formal tests of swallowing function
Referral for swallowing dysfunction
Offer of feeding tube
(continued)
Cheng et al. 975Table 2. Continued
Domain Abbreviated text of MS indicators that met thresholds for validity
General health domains of MS care
At Time of Diagnosis: Medical Evaluation—Appropriateness
and Timeliness
Documentation of diagnostic criteria
Timely initial diagnosis
At Time of Diagnosis: Patient Education Explanation of diagnostic work-up
Offer of information to newly diagnosed patient
Management of Exacerbations and Activities of Daily Living
(ADL) Difficulties
Rehabilitation evaluation following an exacerbation
Assessment of ADL difficulties
Rehabilitation evaluation for ADL difficulties
Treatment with steroids
Communication of risks and benefits of steroids
Comprehension of risks and benefits of steroids
After Diagnosis: Patient Education Assessment for informational needs
Disease-Modifying Agents Treatment of clinically isolated syndrome
Disease-modifying agents for relapsing forms of MS
Lab tests for persons on interferon beta therapy
Lab tests for persons on high-dose interferon beta therapy
Documentation when starting mitoxantrone or natalizumab
Cardiac monitoring with mitoxanthrone
Communication of risks and benefits of disease-modifying treatments
Comprehension of risks and benefits of disease-modifying treatments
Provision of Community and Social Resources/Patient
Self-Management
Assessment of problems with work or education
Management of temperature
Complementary and alternative medications
Establishment, Integration, and Coordination of Care Visit to neurologist or physiatrist
Access to primary care provider
Follow-up of new medication
Contact for usual source of care
Documentation of consultation by referring physician
Health Promotion Assessment of exercise habits
Recommendation of exercise
Assessment of general symptoms
General Preventive Care Mammogram
Pap smear
Colon cancer screening
Influenza immunization
Pneumococcal polysaccharide vaccine
Osteoporosis screening
Health Insurance and Disability Programs Awareness of health insurance and disability programs
976 Multiple Sclerosis 16(8)experience of measuring care, we concluded that 12
indicators can be obtained through administrative
data but that the other 64 indicators require chart
abstraction or patient surveys; of those 12 indicators
that can be obtained through administrative data, six
are in the domain of general preventive care, and three
concern surveillance for adverse eﬀects of disease-
modifying agents.
Discussion
Although MS presents with a wide range of symptoms,
our multidisciplinary panel reached consensus on which
MS symptoms were most important in each mobility
stage of the disease. Such symptoms are among those
known to have a strong association with health-related
quality of life among persons with MS.
5,28 Among the
general health domains of MS care, the domain of
disease-modifying agents was highly ranked, consistent
with the large number of RCTs, meta-analyses, and
guidelines that recommend their usage.
29,30 Perhaps
less predictable was that the timeliness and appropri-
ateness of the diagnostic workup was just as highly
rated. However, our interviews with persons with MS
conﬁrmed ﬁndings reported in other qualitative studies
that some persons with MS still exhibited anger for
being misdiagnosed for years or relief at ﬁnally being
given a correct diagnosis.
31–33 Also noteworthy are
some indicators that did not meet thresholds of valid-
ity. The lowest rated indicator was antibody testing for
persons using beta-interferon. Competing guidelines
recommend diﬀerent courses of action about this
topic, reﬂecting uncertainty among experts.
34,35
There is a long-standing debate within the ﬁeld of
health services research on the advantages and disad-
vantages of using patient outcomes versus medical
Table 3. Number of indicators by domain rated by Panel 2, and number of indicators that met thresholds for validity.
Domain Name
Number of
indicators rated
by Panel 2
Number of
indicators that met
threshold for validity
Domains of MS symptoms
Anxiety 1 1
Bladder Dysfunction/Urinary Tract Infection (UTI) 6 6
Bowel Dysfunction 4 3
Cognitive Dysfunction 2 2
Depression 2 2
Fatigue 4 4
Mobility/Falls 2 2
Pneumonia 1 0
Pressure Ulcer 4 4
Relapses 3 2
Sexual Dysfunction 5 5
Spasticity 3 3
Speech 1 1
Swallowing 6 4
General health domains of MS care
At Time of Diagnosis: Medical Evaluation-Appropriateness and Timeliness 2 2
At Time of Diagnosis: Patient Education 2 2
Management of Exacerbations and Activities of Daily Living Difficulties 6 6
After Diagnosis: Patient Education 1 1
Disease-Modifying Agents 9 8
Provision of Community and Social Resources/Patient Self-Management 6 3
Establishment, Integration, and Coordination of Care 6 5
Health Promotion 3 3
General Preventive Care 6 6
Health Insurance and Disability Programs 1 1
Totals 86 76
Cheng et al. 977processes of care to measure quality of care.
7 While all
stakeholders recognize that patient outcomes are extre-
mely important, patient outcomes can be strongly asso-
ciated with unmodiﬁable characteristics such as patient
age. Therefore, to compare patient outcomes across
populations, one needs to perform risk adjustment.
The advantages of measuring medical care processes
are that they are less likely to be sensitive to risk adjust-
ment, and they represent an aspect of care that clini-
cians most directly control. However, if processes alone
are used to measure quality, it may be necessary to
conﬁrm the link between performance of medical pro-
cesses and improved patient outcomes.
36,37
Measurement programs may diﬀer in how they select
indicators for implementation. Online Table 3 is pro-
vided as a sortable spreadsheet so that readers may
prioritize criteria for selecting valid indicators.
Programs with a small number of persons with MS
should only choose indicators that are expected to be
triggered frequently. Programs that use indicators for
accountability purposes will prefer those that are sup-
ported by RCTs or by key healthcare organizations.
Indicators measurable through administrative data are
seemingly ideal, but we caution that such indicators
originate from only a few domains. In addition, indica-
tors measurable through administrative data may over-
estimate overall care quality because those care
processes may be easier to perform. A large study of
geriatric care implemented 145 quality indicators that
could only be measured by reviewing the medical records,
and adherence to these indicators was 55%; in the same
study, 37 other quality indicators were measured using
administrative data and medical record review, and the
study determined that adherence to these indicators was
83%foreithertechnique.
38Tofacilitatemeasurementofa
comprehensivesetofindicatorsthatdonotrelyonadmin-
istrative data, we plan to develop and pilot-test a medical
chart abstraction tool and patient survey to measure care
for persons with MS.
The 86 indicators presented to Panel 2 are based on a
literature review and are not country-speciﬁc. Prior
studies show that most indicators can be transferred
to another country, but only after they are reviewed
by clinicians in that country to allow for international
variations in clinical practice.
39,40
We developed a set of indicators for measuring the
comprehensive care of persons with MS. The tradi-
tional application of indicators has been in health ser-
vices research studies that measure whether persons are
receiving appropriate care. However, in today’s health-
care environment, we envision a potentially broader use
of these indicators such as certifying standards for MS
centers, maintenance of board certiﬁcation for health-
care providers, and application in pay-for-performance
programs.
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